Regulatory response to drugmaker woes not expected to slow biotech growth

01/3/2005 | Bloomberg Businessweek

The troubles experienced by several companies in the pharmaceutical industry this past year have left biotech investors concerned the FDA will have to clamp down on safety problems affecting biotech firms along with drugmakers. Nonetheless, Ernst & Young International foresees no slowdown in sales of biotech drugs and vaccines, with industry revenues expected to rise to $51.4 billion this year, a 19.5% increase over revenues expected to be reported for 2004.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC